PFW Advisors LLC Purchases New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

PFW Advisors LLC acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 25,990 shares of the company’s stock, valued at approximately $573,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TEVA. Stifel Financial Corp boosted its holdings in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after acquiring an additional 23,283 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $24,314,000. CWA Asset Management Group LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $3,340,000. Finally, Two Sigma Advisers LP increased its stake in Teva Pharmaceutical Industries by 15.3% during the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.52 during mid-day trading on Monday, reaching $20.42. 15,174,058 shares of the company traded hands, compared to its average volume of 9,156,907. Teva Pharmaceutical Industries Limited has a 52 week low of $10.83 and a 52 week high of $22.80. The firm has a market cap of $23.13 billion, a PE ratio of -24.02, a PEG ratio of 0.99 and a beta of 0.73. The company’s 50 day moving average price is $18.89 and its 200-day moving average price is $18.05. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.